P-179_Peptides

www.peptidesevent.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
A: Cyclic Peptides: Discovery,
Development and Deployment
Workshop Leaders:
Dan Teufel, Head of Chemistry, Bicycle Therapeutics Limited
Roger New, Co founder and CSO, Proxima Concepts Ltd
08.30 – 12.30
B: Cupid Cell Penetrating Peptides
– A Powerful New Tool For Cellular Research
Workshop Leader:
Jonathan Ryves, Director, Cupid Peptides
13.30 – 17.30
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 5th July 2016, Holiday Inn Kensington Forum, London, UK
REGISTER BY 31ST MARCH AND RECEIVE A £500 DISCOUNT
REGISTER BY 29TH APRIL AND RECEIVE A £300 DISCOUNT
REGISTER BY 27TH MAY AND RECEIVE A £200 DISCOUNT
@SMIPHARM
#SMiPeptides
SMi Present the 3rd Annual Conference on…
Peptides
Holiday Inn Kensington Forum, London, UK
6 - 7
JULY
2016
Exploring the latest innovations in
pre-clinical peptide development to facilitate
the advancement of next generation peptides
Exclusive Highlights in 2016:
• MEDI0382, a novel GLP1/glucagon co-agonist, as a
promising therapeutic lead for the treatment of Type 2
diabetes and obesity
• Oral peptide delivery technology landscape
• Puriﬁcation of synthetic peptides by reversed phase
chromatography
• Strategies for peptide-based vaccines development for
antiviral diseases
• Live learning lab: Strategy for successful GMP peptide
development, scale-up and manufacturing
Sponsored by
Chairs for 2016:
Lutz Jermutus, Senior Director, R&D and Product
Development Team Leader, MedImmune
Dan Teufel, Head of Chemistry,
Bicycle Therapeutics
Featured Speakers:
• Leila Hassani-Beniddir, Senior Scientist - Novel Drug Delivery
Technologies , Ipsen Limited
• Mathias Schaffrath, Group Leader Chromatography,
Sanoﬁ-Aventis
• Saif Shubber, Scientist, MedImmune
• Ashok Bhandari, Vice President, Chemistry,
Protagonist Therapeutics
• Oliver Demmer, Innovation Consultant, Ministry of Foreign
Affairs of Denmark

Peptides
Day One | Wednesday 6th July 2016
Register online at: www.peptidesevent.com • Alternatively fax yo
Sponsored by
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
OPENING ADDRESS
09.10 MEDI0382, a novel GLP1/glucagon co-agonist,
as a promising therapeutic lead for the treatment of
Type 2 diabetes and obesity
• Pre-clinical summary
• Clinical summary
• Mechanism of action studies
09.50 Purification of synthetic peptides by reversed phase
chromatography
• High Throughput purification by automation
• Mass triggered fractioning
• High quality and good recovery of the final product
Mathias Schaffrath, Group Leader Chromatography,
Sanofi-Aventis
10.30 Morning Coffee
10.50 Peptide materials for the targeted and responsive delivery
of therapeutics
• Background to self-assembling peptides
• Design of sprayable and injectable delivery devices
• How to control the temporal release of therapeutics
• Exemplars for the delivery of small molecules, protein
therapeutics and mRNA
Aline Miller, Professor of Biomolecular Engineering,
University of Manchester
TECH TALK BY SPONSOR
11.30 Assessing immunogenicity in peptide development
• T-cell help as a risk factor in the development of
anti-drug antibodies
• Immunogenicity of peptides data updates
• Deimmunisation of naturally immunogenic non-human
protein therapeutics
Gary Bembridge, Director of Scientific
Affairs Immunology, Abzena
12.10 Networking Lunch
13.30 Live learning lab: Strategy for successful GMP
peptide development, scale-up and manufacturing
This interactive session will provide live insights related
to process and analytical development, management
of external supply operations. As well as demonstrate a life
cycle approach to manufacturing of peptide APIs including
process and regulatory dimensions.
• Challenges and decision points from early process
development
• Scaling-up: Strategy and cost optimisation
• Validation and regulatory requirements
• Contract manufacturing and outsourcing management
Vincent R. Bille, Founder and Managing Director,
Marble Pharma Consult
14.30 Oral peptide delivery technology landscape
• Current status
• Particular considerations or oral peptide delivery
• Approaches and strategies for oral peptide delivery
Leila Hassani-Beniddir, Senior Scientist - Novel Drug
Delivery Technologies, Ipsen
15.10 Discovery of novel and potent orally stable peptide
antagonists of the human IL-23 receptor and their pre-
clinical POC in rat colitis models
• Discovery of novel peptides antagonist for human IL-23
receptor that are
• Orally stable, GI restricted
• Efficacious in rat TNBS colitis model
Ashok Bhandari, Vice President, Chemistry,
Protagonist Therapeutics
15.50 Afternoon Tea
16.15 Using Cupid, a novel cell penetrating peptide, to carry
GFP into cells
• Advances in Cupid CPP technology
• Applications in stem cell research
• Looking to the future
16.55 Design of the theranostic CXCR4 ligand Pentixafor and its
application in man
• Design of Pentixafor: N-methylated, cyclic peptides,
dimers and peptoids
• Optimisation of N-methylation/alkylation procedures
and other peptide modifications
• Efficient on-resin strategies for the synthesis of branched
and modified peptides
• PET imaging in man for cancer diagnosis using Pentixafor
Oliver Demmer, Innovation Consultant,
Ministry of Foreign Affairs of Denmark
17.35 Chairman’s Closing Remarks and Close of Day One
Abzena offers a suite of complementary services and technologies.
Its range of technologies include immunogenicity assessment,
antibody drug conjugation, protein engineering, PEGylation, cell
line development, GMP manufacturing and a range of bespoke
assays to enables the development of better biopharmaceuticals
which will have a greater chance of reaching the market.
www.abzena.com
Bachem provides comprehensive services to the pharma and
biotech industries. It specializes in the development of innovative,
efficient manufacturing processes and the reliable production
of peptide-based APIs. The group has a global reach with more
experience and know-how than any other company in the industry.
Bachem. Pioneering Partner for Peptides www.bachem.com
Sponsorship and Exhibition Opportunities
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored
to complement your company’s marketing
strategy. Prime networking opportunities exist to
entertain, enhance and expand your client base
within the context of an independent discussion
specific to your industry.
Should you wish to join the increasing number
of companies benefiting from sponsoring our
conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk
FORMULATION AND DEVELOPMENT
EXCLUSIVE TRAINING SESSION
ORAL PEPTIDES AND NOVEL TECHNOLOGIES

Peptides
Day Two | Thursday 7th July 2016
08.30 Registration and Coffee
09.00 Chairman’s Opening Remarks
OPENING ADDRESS
09.10 New synthetic anti tuberculosis cyclohexylgriselimycin,
more than 50 years after the isolation of the natural
griselimycin
• Case study in peptide chemistry
• Modern day optimisation of the natural compound
Griselimycin (GM)
• Novel mode of action and anti-TB properties
Evelyne Fontaine, Medicinal Chemist, Sanofi
TECH TALK BY SPONSOR
09.50 CMC case study: Process development, commercial
manufacturing and quality control for generic peptide APIs
• Chemical process development, scale-up and large
scale manufacturing of the two generic peptide APIs
Atosiban and Lanreotide
• Analytical control strategy (starting material quality,
in-process controls, API specifications)
• Comparison of process parameters and drug
substance quality attributes from process performance
qualification and commercial manufacturing
Daniel Samson, Senior Director
API Manufacturing, Bachem
10.50 Development of cytotoxic bicyclic peptide drug
conjugates and applications in molecular targeted
cancer therapy
• Peptide drug development
• Toxin conjugate development
• Radio-nuclide conjugates, biodistribution
• Formulation (possibly), physchem etc
• In vitro/vivo results
11.30 Developing a peptide coagulant and formulation to treat
traumatic bleeding
• Unmet needs in the control of traumatic bleeding
• Design of peptide coagulant and formulation
• Progress to date
Renata Zbozien, VP Research, Haemostatix Ltd
12.10 Networking Lunch
13.30 Enhanced drug delivery with Veltis® engineered albumins
• Short circulatory half-life represents a major obstacle for
many peptide-based therapeutics
• This can be significantly improved by conjugation or
fusion to albumin, due to increased size and recycling
via the neonatal Fc receptor (FcRn)
• The increased FcRn affinity of the Veltis® engineered
albumins translates to more than doubling of the already
long half-life of native sequence albumin
• We will describe rationally engineered albumins and
their application to improve delivery of peptides
Joanna Hay, Science Manager, Albumedix
14.10 Unlocking the therapeutic potential of peptide stability
• Peptides as pharmaceutical drugs
• Challenges to their formulation and delivery
• Overcoming the challenges
• Formulation development and drug delivery
• Future directions and conclusions
Saif Shubber, Scientist, MedImmune
14.50 Afternoon Tea
15.20 Strategies for peptide-based vaccines development for
antiviral diseases
• Identification of potentially protective epitopes
• Design and conjugation of conformationally constrained
epitopes
• Strategies to enhance immunogenicity
Elisabetta Bianchi, Head of Peptide Chemistry,
IRBM Science Park S.p.A.
16.00 Vaccination via the oral route
• Strategies for delivery to Peyer’s Patches
• Deployment of sub-unit vaccines
• Success in challenge models
Roger New, Co-founder and CSO, Proxima Concepts Ltd
16.40 Chairman’s Closing Remarks and Close of Day Two
our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Honey De Gracia, SMi Marketing on +44 (0) 207 827 6102 or email: hdegracia@smi-online.co.uk
Supported by
INNOVATIONS IN PEPTIDES
OVERCOMING THE CHALLENGES
Official Media Partners

A: Cyclic Peptides: Discovery,
Development and Deployment
Workshop Leaders:
Dan Teufel, Head of Chemistry,
Bicycle Therapeutics Limited
Roger New, Co Founder & CSO, Proxima Concepts Ltd
HALF-DAY PRE-CONFERENCE WORKSHOP
Tuesday 5th July 2016
08.30 – 12.30
Overview of Workshop:
A number of cyclic peptides are already known as successful
drugs for treatment of disease, and this workshop will discuss the
reasons why cyclic peptides will continue to show increased
potential as therapeutic agents in the future. The advantages
and disadvantages of working with cyclic peptides will be
discussed, and different methods for discovery of active
compounds will be described. This is followed by discussion
on preclinical development and manufacture of candidate
peptide-based therapeutics, and finally, examples will be
given of their application in treatment of models for disease.
Programme:
09.00 Discovery methodologies
• Why cyclic peptides will continue to show
increased potential
10.00 The development process
• An overview of working with cyclic peptides
• Methods for discovery of active compounds
11.30 Applications in medicine
• Current and future applications in treatment
of models for disease
12.30 End of Workshop
About the Workshop Leaders:
Roger New studied chemistry at Oxford and obtained a PhD
in immunology at St Mary’s Hospital, London, before going to
work first at the Department of Biochemistry, then at the School
of Tropical Medicine and Hygiene. His research activities have
centered on the creation of new technologies to improve the
therapy of disease, during which time he has devised patented
approaches to oral peptide delivery, vaccine carrier systems,
and a technology for discovery of new therapeutics. Dr New’s
laboratory was the first to demonstrate the in vivo efficacy of
liposomal amphotericin in leishmaniasis, a product which has
now been commercialised for over ten years. He went into
industry twenty years ago, fi rst in Biocompatibles Ltd, then
Cortecs, and is currently Co-founder and Executive Director of
the biotech R&D company Proxima Concepts Ltd.
Dan Teufel has over 15 years of experience in the field of
peptide/protein chemistry and biophysics, has authored
numerous publications and is inventor of a dozen patents.
He has earned his PhD from the University of Cambridge, UK.
He has also worked at the Centre for Protein Engineering and
the Laboratory of Molecular Biology in Cambridge, Harvard
Medical School in Boston, and DSM in the Netherlands. Later,
he worked with one of the founders of Bicycle Therapeutics,
Sir Gregory Winter, on the early Bicycle Project. After the
foundation of Bicycle Therapeutics in 2009, he joined the
Company as its first scientist. He is currently developing several
Bicyclic Peptide candidates towards application in the clinic,
including toxin linked conjugates.
About the Organisations:
Proxima Concepts was founded in 2000, and has devised four
new technologies which it is exploiting in the biopharmaceutics
area:
1. Axcess – a vehicle for oral delivery of
peptides and proteins, including oral insulin in
Phase II
2. Vaxcine – an oil-based delivery vehicle
for oral administration of vaccine antigens, with particular
application to intestinal and respiratory diseases.
3. Mozaic – a discovery technology for identifying building
blocks which, in combination, can form therapeutically active
structures.
Bicycle Therapeutics is a UK biotech developing
highly constrained bicyclic peptides (Bicycles)
as a novel class of therapeutic. Bicycles
have the affinity and specificity associated
with antibodies, but are much smaller in size and can be
chemically synthesised. They have been shown to address
targets not easily tractable with small molecules (e.g. protein-
protein interactions).The company is exploring applications in
a number of areas where these advantageous features have
the potential to show significant benefit, including toxin-linked
conjugates for molecular targeted cancer therapy.

B: Cupid Cell Penetrating
Peptides – A Powerful New Tool
For Cellular Research
Workshop Leader:
HALF-DAY PRE-CONFERENCE WORKSHOP
Tuesday 5th July 2016
13.30 – 17.30
Overview of Workshop:
Cell penetrating peptides (“CPPs”) have a huge role to
play in both research and drug delivery. However, the
majority of bio-medical researchers rarely use the most
sophisticated CPPs available and research using these
valuable tools has been slow. Whatever the reasons for
this, it has hampered progress in understanding how
proteins interact with each other inside human cells.
In this Workshop Dr Ryves will cover the important
aspects of Cell Penetrating Peptide (CPP) technology
and educate the audience on how to get the most
of the CPP’s available on the market today to further
develop their research in the peptide arena.
Programme:
14.00 An introduction to CPPs
• What are CPPs? Discovery and
development
• A look at the different types of CPPs
and their strengths and weaknesses
• Using CPPs in Biomedical research
14.45 An introduction to Cupid
• Demonstrating its capabilities using
Cupid-GFP Protein
15.30 Afternoon Tea
16.00 The Future of CPPs - Therapeutic applications
• Cupid Stem Cell Project
16.45 How can CPPs work for you?
• Real problems and solutions
17.30 End of Workshop
About the Workshop Leader:
Dr W Jonathan Ryves founded Cupid Peptides in 2012.
He has over 25 years’ experience in Protein Biochemistry
and Molecular Biology working in UCL and Cardiff
University and has co-authored over 40 peer-reviewed
scientific publications. With over 10 years experience in
Cell Penetrating Peptide (CPP) research, he is pioneering
the practical use of “Cupid”, the most powerful form
of CPP, as a technology platform for Biomolecular
Researchers to understand protein-protein interactions.
About the Organisation:
Cupid Peptides designs and manufactures high-purity
synthetic molecules linking our proprietary CPP3 to any
protein.Weworkwithacademicandresearchinstitutions
keen to understand the role of these proteins in complex
processes such as cancer and inflammation. Cupid
Technology offers the researcher Speed – Cargoes are
bioactive in 30-60 mins Control – Using GFP fluorescence
to monitor Cupid-Cargo entry Versatility - Mutant
proteins or parts of proteins can also be delivered into
cells allowing proteins to be functionally
‘mapped’ giving valuable insight into how
proteins are involved in disease.

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferencesdocumentationviatheDocumentPortaltoanydelegatewhohaspaidbutisunable
to attend for any reason. Due to the interactive nature of the Brieﬁngs we are not normally able
to provide documentation in these circumstances. We cannot accept cancellations of orders
placed for Documentation or the Document Portal as these are reproduced speciﬁcally to order.
If we have to cancel the event for any reason, then we will make a full refund immediately, but
disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about
other products and services. Unless you tick here □ we may also share your data with third parties
offeringcomplementaryproductsorservices.Ifyouhaveanyqueriesorwanttoupdateanyofthe
data that we hold then please contact our Database Manager databasemanager@smi-online.
co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your
address on the attached letter.
Payment must be made to SMi Group Ltd, and received before the event, by one of the
following methods quoting reference P-179 and the delegate’s name. Bookings made within
7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
□ Book by 31st March to receive £500 off the conference price
□ Book by 29th April to receive £300 off the conference price
□ Book by 27th May to receive £200 off the conference price
EARLY BIRD
DISCOUNT
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop A □ B □ £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops £1198.00 + VAT £1437.60
□ 1 Workshop only £599.00 + VAT £718.80
Workshop A □ Workshop B □
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Unique Reference Number
Our Reference LVP-179
DELEGATE DETAILS
Terms and Conditions of Booking
PAYMENT
VAT
CONFERENCE PRICES
DOCUMENTATION
VENUE Holiday Inn Kensington Forum, 97 Cromwell Rd, London SW7 4DN, UK
PEPTIDES
Conference: Wednesday 6th & Thursday 7th July 2016, Holiday Inn Kensington Forum, London, UK Workshops: Tuesday 5th July 2016, London, UK
4 WAYS TO REGISTER
www.peptidesevent.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK

P-179_Peptides

Recommended

Recommended

More Related Content

Similar to P-179_Peptides

Similar to P-179_Peptides (20)

More from Kiran Bains

More from Kiran Bains (11)

P-179_Peptides